Corcept Therapeutics Inc. | Mid-cap | Healthcare
$71.75
-0.35%
| Corcept Therapeutics Stock Comparison:
Corcept Therapeutics vs VertexCorcept Therapeutics vs RegeneronCorcept Therapeutics vs ModernaCorcept Therapeutics vs BridgeBio PharmaCorcept Therapeutics vs Blueprint MedicinesCorcept Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 157.2M
Gross Profit 154.8M 98.47%
Operating Income 3.4M 2.17%
Net Income 20.5M 13.07%
EPS (Diluted) $0.17

Balance Sheet Metrics

Total Assets 846.5M
Total Liabilities 163.2M
Shareholders Equity 683.3M
Debt to Equity 0.24

Cash Flow Metrics

Operating Cash Flow 34.7M
Free Cash Flow 5.0M

Revenue & Profitability Trend

Corcept Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i675.0M482.4M401.9M366.0M353.9M
Cost of Goods Sold i10.9M6.5M5.4M5.3M5.6M
Gross Profit i664.2M475.9M396.5M360.7M348.3M
Gross Margin % i98.4%98.7%98.7%98.6%98.4%
Operating Expenses
Research & Development i246.9M184.4M131.0M113.9M114.8M
Selling, General & Administrative i280.3M184.3M152.8M122.4M105.3M
Other Operating Expenses i-----
Total Operating Expenses i527.2M368.6M283.8M236.2M220.1M
Operating Income i137.0M107.3M112.6M124.5M128.2M
Operating Margin % i20.3%22.2%28.0%34.0%36.2%
Non-Operating Items
Interest Income i24.5M17.3M3.6M529.0K3.4M
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i161.5M124.6M116.2M125.0M131.6M
Income Tax i20.3M18.4M14.8M12.5M25.6M
Effective Tax Rate % i12.6%14.8%12.7%10.0%19.4%
Net Income i141.2M106.1M101.4M112.5M106.0M
Net Margin % i20.9%22.0%25.2%30.7%30.0%
Key Metrics
EBITDA i138.3M109.6M116.1M128.0M130.4M
EPS (Basic) i$1.35$1.02$0.95$0.97$0.92
EPS (Diluted) i$1.23$0.94$0.87$0.89$0.85
Basic Shares Outstanding i103232000103560000106787000115653000115412000
Diluted Shares Outstanding i103232000103560000106787000115653000115412000

Income Statement Trend

Corcept Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i127.7M135.6M66.3M77.6M76.2M
Short-term Investments i255.7M232.7M365.3M145.9M364.5M
Accounts Receivable i54.0M41.1M31.1M27.6M26.2M
Inventory i12.4M7.7M6.1M5.0M4.9M
Other Current Assets6.1M27.6M16.4M10.3M-
Total Current Assets i471.6M458.6M499.3M266.5M478.5M
Non-Current Assets
Property, Plant & Equipment i8.0M315.0K1.8M514.0K2.5M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets141.1M105.4M77.5M43.5M52.8M
Total Non-Current Assets i369.0M162.9M84.2M157.3M93.2M
Total Assets i840.6M621.5M583.4M423.8M571.7M
Liabilities
Current Liabilities
Accounts Payable i15.4M17.4M12.0M6.9M10.6M
Short-term Debt i829.0K151.0K1.1M526.0K2.0M
Current Portion of Long-term Debt-----
Other Current Liabilities2.3M654.0K763.0K296.0K-
Total Current Liabilities i140.8M104.5M72.5M47.5M47.5M
Non-Current Liabilities
Long-term Debt i6.1M--0501.0K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i20.2M10.3M9.1M409.0K899.0K
Total Liabilities i161.0M114.8M81.6M48.0M48.4M
Equity
Common Stock i136.0K133.0K131.0K127.0K122.0K
Retained Earnings i543.7M402.5M296.4M195.0M82.5M
Treasury Stock i696.2M635.1M456.1M410.4M75.8M
Other Equity-----
Total Shareholders Equity i679.6M506.7M501.8M375.8M523.3M
Key Metrics
Total Debt i6.9M151.0K1.1M526.0K2.6M
Working Capital i330.8M354.1M426.8M218.9M431.0M

Balance Sheet Composition

Corcept Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i141.2M106.1M101.4M112.5M106.0M
Depreciation & Amortization i1.3M2.4M3.4M3.5M2.2M
Stock-Based Compensation i61.4M48.9M42.4M42.9M33.5M
Working Capital Changes i-682.0K-5.8M-15.6M-1.7M-11.4M
Operating Cash Flow i163.0M122.2M99.1M161.6M145.9M
Investing Activities
Capital Expenditures i-2.2M-139.0K-413.0K-469.0K-1.2M
Acquisitions i-----
Investment Purchases i-588.3M-328.7M-355.1M-312.8M-420.1M
Investment Sales i412.9M419.8M241.2M449.4M302.1M
Investing Cash Flow i-177.6M90.9M-114.3M136.1M-119.3M
Financing Activities
Share Repurchases i0-145.4M0-296.0M-9.9M
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i-22.3M-154.5M-21.7M-318.8M-11.0M
Free Cash Flow i195.9M126.9M119.9M167.4M150.7M
Net Change in Cash i-36.9M58.5M-36.9M-21.1M15.6M

Cash Flow Trend

Corcept Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 64.06
Forward P/E 41.00
Price to Book 11.88
Price to Sales 10.56
PEG Ratio -21.78

Profitability Ratios

Profit Margin 18.67%
Operating Margin 13.72%
Return on Equity 21.70%
Return on Assets 8.36%

Financial Health

Current Ratio 3.06
Debt to Equity 1.04
Beta 0.20

Per Share Data

EPS (TTM) $1.12
Book Value per Share $6.04
Revenue per Share $6.90

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cort7.6B64.0611.8821.70%18.67%1.04
Vertex 100.4B27.855.8422.77%31.86%8.89
Regeneron 61.5B14.622.0215.34%31.37%9.04
Moderna 10.9B24.971.16-27.50%-94.31%7.88
BridgeBio Pharma 9.8B-17.82-5.5036.76%98.25%-1.04
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.